Literature DB >> 22184117

The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1).

Bénédicte Foveau1, Gaylor Boulay, Sébastien Pinte, Capucine Van Rechem, Brian R Rood, Dominique Leprince.   

Abstract

The tumor suppressor gene hypermethylated in cancer 1 (HIC1), which encodes a transcriptional repressor, is epigenetically silenced in many human tumors. Here, we show that ectopic expression of HIC1 in the highly malignant MDA-MB-231 breast cancer cell line severely impairs cell proliferation, migration, and invasion in vitro. In parallel, infection of breast cancer cell lines with a retrovirus expressing HIC1 also induces decreased mRNA and protein expression of the tyrosine kinase receptor EphA2. Moreover, chromatin immunoprecipitation (ChIP) and sequential ChIP experiments demonstrate that endogenous HIC1 proteins are bound, together with the MTA1 corepressor, to the EphA2 promoter in WI38 cells. Taken together, our results identify EphA2 as a new direct target gene of HIC1. Finally, we observe that inactivation of endogenous HIC1 through RNA interference in normal breast epithelial cells results in the up-regulation of EphA2 and is correlated with increased cellular migration. To conclude, our results involve the tumor suppressor HIC1 in the transcriptional regulation of the tyrosine kinase receptor EphA2, whose ligand ephrin-A1 is also a HIC1 target gene. Thus, loss of the regulation of this Eph pathway through HIC1 epigenetic silencing could be an important mechanism in the pathogenesis of epithelial cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22184117      PMCID: PMC3285316          DOI: 10.1074/jbc.M111.329466

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses.

Authors:  Wen Yong Chen; David H Wang; Raywhay Chiu Yen; Jianyuan Luo; Wei Gu; Stephen B Baylin
Journal:  Cell       Date:  2005-11-04       Impact factor: 41.582

2.  Q2ChIP, a quick and quantitative chromatin immunoprecipitation assay, unravels epigenetic dynamics of developmentally regulated genes in human carcinoma cells.

Authors:  John Arne Dahl; Philippe Collas
Journal:  Stem Cells       Date:  2007-02-01       Impact factor: 6.277

3.  Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility.

Authors:  Alice Bjerregaard Larsen; Mikkel Wandahl Pedersen; Marie-Thérése Stockhausen; Michael Vibo Grandal; Bo van Deurs; Hans Skovgaard Poulsen
Journal:  Mol Cancer Res       Date:  2007-03       Impact factor: 5.852

4.  A conditional feedback loop regulates Ras activity through EphA2.

Authors:  Madhu Macrae; Richard M Neve; Pablo Rodriguez-Viciana; Christopher Haqq; Jennifer Yeh; Chira Chen; Joe W Gray; Frank McCormick
Journal:  Cancer Cell       Date:  2005-08       Impact factor: 31.743

5.  A L225A substitution in the human tumour suppressor HIC1 abolishes its interaction with the corepressor CtBP.

Authors:  Nicolas Stankovic-Valentin; Alexis Verger; Sophie Deltour-Balerdi; Kate G R Quinlan; Merlin Crossley; Dominique Leprince
Journal:  FEBS J       Date:  2006-06-07       Impact factor: 5.542

6.  Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.

Authors:  Deepti B Ramnarain; Seongmi Park; Diana Y Lee; Kimmo J Hatanpaa; Shane O Scoggin; Hasan Otu; Towia A Libermann; Jack M Raisanen; Raheela Ashfaq; Eric T Wong; Julian Wu; Robert Elliott; Amyn A Habib
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

7.  Mechanism of fibroblast growth factor-binding protein 1 repression by TGF-beta.

Authors:  Victorino R Briones; Shiyou Chen; Anna Tate Riegel; Robert J Lechleider
Journal:  Biochem Biophys Res Commun       Date:  2006-04-25       Impact factor: 3.575

Review 8.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

9.  The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas.

Authors:  Liping Han; Ziming Dong; Yuhuan Qiao; Gunnar B Kristensen; Ruth Holm; Jahn M Nesland; Zhenhe Suo
Journal:  Gynecol Oncol       Date:  2005-08-02       Impact factor: 5.482

10.  The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.

Authors:  Dana M Brantley-Sieders; Guanglei Zhuang; Donna Hicks; Wei Bin Fang; Yoonha Hwang; Justin M M Cates; Karen Coffman; Dowdy Jackson; Elizabeth Bruckheimer; Rebecca S Muraoka-Cook; Jin Chen
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

View more
  19 in total

1.  Hypermethylated in cancer 1 (HIC1) recruits polycomb repressive complex 2 (PRC2) to a subset of its target genes through interaction with human polycomb-like (hPCL) proteins.

Authors:  Gaylor Boulay; Marion Dubuissez; Capucine Van Rechem; Antoine Forget; Kristian Helin; Olivier Ayrault; Dominique Leprince
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

2.  Metabolic inflexibility impairs insulin secretion and results in MODY-like diabetes in triple FoxO-deficient mice.

Authors:  Ja Young Kim-Muller; Shangang Zhao; Shekhar Srivastava; Yves Mugabo; Hye-Lim Noh; YoungJung R Kim; S R Murthy Madiraju; Anthony W Ferrante; Edward Y Skolnik; Marc Prentki; Domenico Accili
Journal:  Cell Metab       Date:  2014-09-25       Impact factor: 27.287

3.  The transcription factor Hypermethylated in Cancer 1 (Hic1) regulates neural crest migration via interaction with Wnt signaling.

Authors:  Heather Ray; Chenbei Chang
Journal:  Dev Biol       Date:  2020-06-02       Impact factor: 3.582

4.  EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System.

Authors:  K R Kampen; F J G Scherpen; G Garcia-Manero; H Yang; G J L Kaspers; J Cloos; C M Zwaan; M M van den Heuvel-Eibrink; S M Kornblau; E S J M De Bont
Journal:  Mol Cancer Res       Date:  2015-05-05       Impact factor: 5.852

5.  DNA double-strand breaks lead to activation of hypermethylated in cancer 1 (HIC1) by SUMOylation to regulate DNA repair.

Authors:  Vanessa Dehennaut; Ingrid Loison; Marion Dubuissez; Joe Nassour; Corinne Abbadie; Dominique Leprince
Journal:  J Biol Chem       Date:  2013-02-15       Impact factor: 5.157

6.  Loss of Hypermethylated in Cancer 1 (HIC1) in breast cancer cells contributes to stress-induced migration and invasion through β-2 adrenergic receptor (ADRB2) misregulation.

Authors:  Gaylor Boulay; Nicolas Malaquin; Ingrid Loison; Bénédicte Foveau; Capucine Van Rechem; Brian R Rood; Albin Pourtier; Dominique Leprince
Journal:  J Biol Chem       Date:  2011-12-22       Impact factor: 5.157

7.  Signification of Hypermethylated in Cancer 1 (HIC1) as Tumor Suppressor Gene in Tumor Progression.

Authors:  Jianghua Zheng; Dan Xiong; Xueqing Sun; Jinglong Wang; Mingang Hao; Tao Ding; Gang Xiao; Xiumin Wang; Yan Mao; Yuejie Fu; Kunwei Shen; Jianhua Wang
Journal:  Cancer Microenviron       Date:  2012-04-13

8.  HIC1 modulates uveal melanoma progression by activating lncRNA-numb.

Authors:  Guangcun Cheng; Jie He; Leilei Zhang; Shengfang Ge; He Zhang; Xianqun Fan
Journal:  Tumour Biol       Date:  2016-07-23

9.  HIC1 interacts with and modulates the activity of STAT3.

Authors:  Ying-Mei Lin; Chia-Mei Wang; Jen-Chong Jeng; Dominique Leprince; Hsiu-Ming Shih
Journal:  Cell Cycle       Date:  2013-07-15       Impact factor: 4.534

Review 10.  Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics.

Authors:  Brian R Rood; Dominique Leprince
Journal:  Expert Opin Ther Targets       Date:  2013-04-09       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.